Life Sciences & MOB Hold Strong Amidst Market Shifts

By Majid Radaei, RadCRE · · Industry Insights

Despite wider CRE headwinds, life sciences and medical office buildings (MOBs) continue to attract substantial investment, driven by sector-specific tailwinds and an estimated $38.5 billion in dry powder allocated to healthcare real estate.

Resilience in Specialized Sectors: Life Sciences and Medical Office Investment

In a commercial real estate landscape marked by fluctuating interest rates and re-evaluated valuations, niche sectors such as life sciences and medical office buildings (MOBs) continue to demonstrate remarkable resilience and attract significant capital. Recent trends indicate that these asset classes are not merely weathering the storm but are positioned for sustained growth, driven by fundamental demand and increasing healthcare expenditures.

Life Sciences: Innovation Drives Demand for Specialized Space

The life sciences sector, encompassing biotechnology, pharmaceuticals, and medical devices, has been a beacon of stability. Despite a cooling in venture capital funding from its 2021 peak, demand for purpose-built lab and R&D space remains robust in key clusters. According to JLL's Q1 2026 Life Sciences Industry Report, vacancy rates for lab space in top U.S. markets like Boston-Cambridge, San Francisco Bay Area, and San Diego, while having softened from historic lows, remain below traditional office averages, often in the mid to high single digits. New developments, such as Alexandria Real Estate Equities' ongoing projects in Kendall Square, continue to see strong pre-leasing activity, underscoring the critical need for highly specialized infrastructure. Blackstone's acquisition of a significant stake in a portfolio of lab properties from a leading developer in 2024, valued at over $1 billion with a reported cap rate in the high 4% to low 5% range, highlights institutional confidence in the long-term prospects of this sector.

Medical Office Buildings: Demographic Tailwinds and Stable Returns

Medical Office Buildings (MOBs), often characterized by their stable income streams and resistance to economic downturns, are also a preferred investment for many institutional and private capital groups. The aging U.S. population and the shift towards outpatient care continue to fuel demand for modern, accessible medical facilities. Data from CommercialSearch reveals that MOB transaction volume, while down from pandemic-fueled highs, remains strong compared to pre-pandemic levels. Average cap rates for MOBs have seen some upward pressure in line with broader market adjustments but generally hover between 5.5% and 6.5% for core assets, reflecting their lower risk profile. Recent significant transactions include Physicians Realty Trust's (DOC) strategic acquisitions of outpatient facilities, demonstrating continued consolidation and optimization within the sector. Analysts at Cushman & Wakefield have noted a particular interest in MOBs located within or adjacent to major hospital systems, which benefit from integrated patient care and referrals.

Capital Allocation and Lender Sentiment

Lenders, while cautious across most CRE sectors, show a comparatively stronger appetite for life sciences and MOB assets. Their sector-specific fundamentals – long-term leases with credit tenants, specialized build-outs that limit fungibility but ensure tenant stickiness, and intrinsic demand – make them attractive. Bridge loans for these assets might see spreads in the SOFR + 350-500 bps range, a noticeable tightening compared to other riskier property types. Permanent financing through CMBS or local banks for stabilized MOBs can achieve spreads around T + 180-250 bps for high-quality assets. The overall market is seeing an estimated $38.5 billion in dry powder specifically targeted for healthcare real estate, according to industry reports, signaling continued significant investment activity.

RadCRE Perspective

"The persistent strength in life sciences and MOBs isn't just about escaping broader market volatility; it's about deep, structural demand. We're advising clients to look beyond the headlines of softening VC funding in life sciences. The best-in-class assets in the primary clusters, particularly those with existing, credit-rated tenants and cutting-edge infrastructure, still command significant premiums. For MOBs, it's about understanding local demographics and healthcare delivery networks. While cap rates have nudged up, they haven't dramatically re-rated like some other asset classes, reflecting the asset's defensive qualities. On the financing side, lenders are showing a clear preference for these sectors. We've been successful in structuring deals for our clients using a combination of regional bank debt for core MOBs and specialized debt funds for more complex life science developments, achieving more favorable terms than what's available for traditional office or even retail. It's about demonstrating the long-term strategic value and the irreplaceable nature of these assets. Don't chase yield blindly; focus on fundamentals and irreplaceable locations."

As the commercial real estate market adjusts to new economic realities, the specialized domains of life sciences and medical office buildings underscore the value of sector-specific expertise and the resilience of assets tied to essential services and innovation. RadCRE continues to guide investors in navigating these attractive, yet nuanced, investment landscapes.

Tags: life sciences real estate, medical office buildings, CRE investment, healthcare real estate, RadCRE, commercial real estate financing, specialized real estate

Sources: JLL, CommercialSearch, Cushman & Wakefield, Blackstone Investor Relations, CoStar, GlobeSt, Commercial Observer